Compare Aecom (ACM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aecom vs Ginkgo Bioworks Holdings Inc — how do they compare? Aecom trades at $68 (market cap $8.69B), while Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $610.13M). The key difference: Aecom is far larger — about 14.2× Ginkgo Bioworks Holdings Inc's market cap, and Aecom pays a 1.76% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| ACM | DNA | |
|---|---|---|
Market Cap | $8.69B | $610.13M |
Sector | Industrials | Health |
52-Week High | $134.35 | $16.14 |
52-Week Low | $66.86 | $5.48 |
Enterprise Value | $10.88B | $647.37M |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
